Figure 5. Control TrkC ligand (IYIY-TEG) has similar immunomodulatory activities as IYIY-I₂-BODIPY.

4T1 tumor bearing mice were administrated with IYIY-TEG via tail vein (equivalent dose to IYIY-I₂-BODIPY) and mice were sacrificed at 2 h and 24 h post administration. Lymphoid organs were harvested and populations of (a) G-MDSCs and Treg cells (b) Th1 (CD4⁺ IFN-γ⁺), Th17 (CD4⁺ IL-17⁺) and (c) CTLs (CD8⁺ IFN-γ⁺), Tc17 (CD8⁺ IL-17⁺) cells were quantified using flow cytometry after labeling with fluorescence conjugated antibodies. Data represent mean ± SEM with minimum of four mice per group. *p < 0.05 vs saline control using student’s t-test.